Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
Venture funding drops again, but there’s no need to panic yet.
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.